
    
      Study drugs are administered for 14 weeks in total, including a 2-week run-in period (single
      blind) and a 12-week treatment period (double blind). After written informed consent, study
      drugs for the run-in period are orally administered once daily after breakfast for two weeks
      to subjects who fulfill the inclusion and exclusion criteria. Then, subjects are randomized
      and orally treated with study drugs for the treatment period once daily after breakfast for
      12 weeks
    
  